| Name | Droperidol |
| Description | Droperidol (Dehydrobenzperidol) is a Dopamine-2 Receptor Antagonist. The mechanism of action of droperidol is as a Dopamine D2 Antagonist. |
| In vitro | Droperidol has a dual effect on repolarization, prolonging the development of EADs and the subsequent triggering of activity in rabbit Purkinje fibers at low concentrations. In rabbit Purkinje fibers stimulated with 60 pulses/min, 0.01 mM-0.3 mM Droperidol increased action potential duration (APD) in a dose-dependent manner without altering other parameters.1 mM-3 mM Droperidol resulted in a reversal of the prolongation effect in rabbit Purkinje fibers.10 mM- 30 mM Droperidol produced a shortening of the APD at 50% repolarization, accompanied by significant reductions in Vmax, action potential amplitude, and resting membrane potential in rabbit Purkinje fibers. A single dose of 3 mg/kg Droperidol not only dose-dependently reduced activity and rearing frequency in the open-field experiment, but also reduced the Apomorphine effect in rats.Droperidol (3 mg/kg, long-term administration) induced significant tolerance to all activity parameters recorded in the rat open field. |
| In vivo | Droperidol has been shown to block potassium efflux from the myocardium of isolated animal ventricular myocytes, resulting in a dose-dependent delay in repolarization.Droperidol also induces early depolarization of Purkinje fibers in isolated animals.Droperidol produces mild alpha-adrenergic blockade and peripheral vasodilation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 65 mg/mL (171.31 mM), Sonication is recommended.
|
| Keywords | NSC169874 | Dopamine Receptor | Droperidol | inhibit | NSC-169874 | Inhibitor |
| Inhibitors Related | Olanzapine | CLOZAPINE N-OXIDE | Mirtazapine | Octopamine hydrochloride | Octodrine | Citicoline | Phenothiazine | Oxolinic acid | Mianserin hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
